The diagnostic cascade for patients with hepatitis delta infection in France, 2018–2022: A cross‐sectional study
Liver International · 2024
DOI: 10.1111/liv.16031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Ségolène Brichler und 6 weiteren Autor:innen. Beteiligte Einrichtung: French National Reference Center for Hepatitis B, C and D Viruses, Laboratoire de Microbiologie Clinique, Hôpital Avicenne, Bobigny, France. Hauptthemen laut MEDLINE: Hepatitis Delta Virus, Hepatitis D, Chronic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims Chronic hepatitis D infection is the most severe form of viral hepatitis and can rapidly progress to cirrhosis or hepatocellular carcinoma. Despite recommendations for systematic screening of hepatitis B surface antigen (HBsAg)‐positive individuals, data from real‐world studies have reported a low frequency of hepatitis D (or delta) virus (HDV) screening. Our cross‐sectional analysis evaluated the diagnostic cascade for hepatitis D infection in tertiary centres and described the characteristics of HDV‐positive patients.
Methods
A total of 6772 individuals who tested HBsAg positive for the first time between 2018 and 2022 were retrospectively included. Demographic, clinical and laboratory data were analysed.
Results
A total of 5748 HBsAg‐positive individuals (84.9%) were screened for HDV infection. The screening rate varied from 63% to 97% according to the screening strategy used in the centres including or not HDV reflex testing. The prevalence of HDV infection was 6.3%. HDV RNA levels were determined in 285 of the 364 (78.3%) HDV antibody screening‐positive patients, and 167 (58.6%) had active HDV infection. 66.8% were males, with a mean age of 44.9 years. A total of 97.5% were born abroad, and 92.9% were HBeAg negative. At the time of diagnosis, HDV RNA levels were 6.0 Log UI/mL; 60.1% had alanine aminotransferase >40 U/L, and 56.3% had significant fibrosis (≥F2), including 41.6% with cirrhosis. The most common genotype was HDV‐1 (75.4%). Coinfections were not uncommon: 7.4% were HIV positive, and 15.0% were HCV antibody positive.
Conclusions
The present study highlights the need for increased screening and monitoring of HDV infection. Reflex testing helps to identify HDV‐infected individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- French National Reference Center for Hepatitis B, C and D Viruses, Laboratoire de Microbiologie Clinique, Hôpital Avicenne, Bobigny, France.
- "Team Viruses, Hepatology, Cancer", Institut de Recherche Biomédicale INSERM U955, Créteil, France.
- Laboratoire de Virologie, CHU Bordeaux, Groupe Hospitalier Pellegrin, Bordeaux, France.
- Department of Virology, Hopital Paul Brousse, Université Paris Saclay, Villejuif, France.
- INSERM U1193, Villejuif, France.
- Laboratoire de Virologie, CHU Toulouse, Hôpital Purpan, Toulouse, France.
ORCID-Profile: Ségolène Brichler, Stéphane Chevaliez
Zitieren
APA
Brichler, S., Trimoulet, P., Roque-Afonso, A. M., Izopet, J., Thibault, V., Roudot-Thoraval, F., & Chevaliez, S. (2024). The diagnostic cascade for patients with hepatitis delta infection in France, 2018–2022: A cross‐sectional study. Liver International. https://doi.org/10.1111/liv.16031
Vancouver
Brichler S, Trimoulet P, Roque-Afonso AM, Izopet J, Thibault V, Roudot-Thoraval F, et al. The diagnostic cascade for patients with hepatitis delta infection in France, 2018–2022: A cross‐sectional study. Liver International. 2024. doi:10.1111/liv.16031
BibTeX
@article{Brichler2024,
author = {Brichler, Ségolène and Trimoulet, Pascale and Roque-Afonso, Anne-Marie and Izopet, Jacques and Thibault, Vincent and Roudot-Thoraval, Françoise and Chevaliez, Stéphane},
title = {The diagnostic cascade for patients with hepatitis delta infection in France, 2018–2022: A cross‐sectional study},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.16031}
}
EUVIMED